Quick Order

EGFR/HER1 Rabbit MAb

  • EGFR / HER1 / ErbB1 Neutralizing Antibody
DatasheetReviewsRelated ProductsProtocols
Human EGFR Antibody Product Information
Immunogen:Recombinant Human EGFR / HER1 / ErbB1 Protein (Catalog#10001-H08H)
Clone ID:RE10
Ig Type:Rabbit IgG
Concentration:
Endotoxin:< 3 EU/mg
Formulation:0.2 μm filtered solution in Histidine and Arginine buffer containing 120mM NaCl, 0.02% Tween 80, pH6.0
Preparation:This antibody was obtained from a rabbit immunized with purified, recombinant Human EGFR / HER1 / ErbB1 (rh EGFR / HER1 / ErbB1; Catalog#10001-H08H; NP_005219; Met1-Ser645) and was produced using recombinant antibody technology.
Human EGFR Antibody Neutralization Application Image
EGFR / HER1 / ErbB1 Neutralizing Antibody
[Click to enlarge image]
Caption:
Cell Proliferation Induced by Autocrine EGF was Neutralized by Human EGFR Antibody. Autocrine EGF stimulates proliferation in the human breast cancer MDA-MB-468 cell line. Proliferation elicited by Autocrine EGF is neutralized by increasing concentrations of Human EGFR Monoclonal Antibody (Catalog 10001-RE10). The IC50 is typically 0.05-0.2 μg/mL.
Other EGFR Antibody Products
Immunochemical staining of human CD40 in human tonsil with rabbit polyclonal antibody (0.5 µg/mL, formalin-fixed paraffin embedded sections).
EGFR/HER1 Background

As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Human EGFR/HER1 References
  • Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2): 211-25.
  • Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann. Oncol. 16(4): 538-48.
  • Yarden, Y., et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2): 127-37.
  • Product nameProduct name
    Size / Price
    Catalog: 10001-RE10-200
    List Price: 
    Price:      (You Save: )

    Datasheet & Documentation

    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"